ES2625153T3 - Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución - Google Patents

Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución Download PDF

Info

Publication number
ES2625153T3
ES2625153T3 ES11761051.9T ES11761051T ES2625153T3 ES 2625153 T3 ES2625153 T3 ES 2625153T3 ES 11761051 T ES11761051 T ES 11761051T ES 2625153 T3 ES2625153 T3 ES 2625153T3
Authority
ES
Spain
Prior art keywords
fii
fibrinogen
fviia
combination
coagulation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11761051.9T
Other languages
English (en)
Spanish (es)
Inventor
Ann Lovgren
Kenny Hansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2625153(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Application granted granted Critical
Publication of ES2625153T3 publication Critical patent/ES2625153T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES11761051.9T 2010-10-06 2011-09-19 Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución Active ES2625153T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06
US390224P 2010-10-06
PCT/EP2011/066241 WO2012045569A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Publications (1)

Publication Number Publication Date
ES2625153T3 true ES2625153T3 (es) 2017-07-18

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11761051.9T Active ES2625153T3 (es) 2010-10-06 2011-09-19 Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución

Country Status (16)

Country Link
US (1) US9433664B2 (enExample)
EP (1) EP2624859B1 (enExample)
JP (1) JP6000259B2 (enExample)
KR (1) KR20130136988A (enExample)
CN (1) CN103221061A (enExample)
AU (1) AU2011313505B2 (enExample)
BR (1) BR112013008034A2 (enExample)
CA (1) CA2812888A1 (enExample)
DK (1) DK2624859T3 (enExample)
ES (1) ES2625153T3 (enExample)
HU (1) HUE033204T2 (enExample)
MX (1) MX343784B (enExample)
PL (1) PL2624859T3 (enExample)
RU (1) RU2606155C2 (enExample)
SG (2) SG10201508159SA (enExample)
WO (1) WO2012045569A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
SG10201508159SA (en) 2010-10-06 2015-10-29 Medimmune Ltd Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
IL230150A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
JP7227905B2 (ja) 2017-02-09 2023-02-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血の処置または予防における使用のための血液凝固因子代替製品
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3165600D1 (en) 1980-01-28 1984-09-27 Baxter Travenol Lab Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
HUP9700603A3 (en) 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
ATE386538T1 (de) 2001-02-05 2008-03-15 Novo Nordisk Healthcare Ag Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
AU2002354846B2 (en) 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1748781B1 (en) 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CA2644926A1 (en) * 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin and fibrinogen
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
WO2008051513A2 (en) 2006-10-23 2008-05-02 Allan Pronovost Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
US20080267940A1 (en) 2007-03-30 2008-10-30 Mohammed Syed F Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
EP2337793A4 (en) 2008-10-08 2013-04-10 Thrombodyne Inc METHOD FOR PRODUCING CONCENTRATED FIBRINOGEN AND PLAIN-CONTAINING COMPOSITIONS
SG10201508159SA (en) 2010-10-06 2015-10-29 Medimmune Ltd Factor II And Fibrinogen For Treatment Of Haemostatic Disorders

Also Published As

Publication number Publication date
AU2011313505A1 (en) 2013-04-11
DK2624859T3 (en) 2017-06-06
SG10201508159SA (en) 2015-10-29
WO2012045569A1 (en) 2012-04-12
CN103221061A (zh) 2013-07-24
AU2011313505B2 (en) 2015-09-17
US9433664B2 (en) 2016-09-06
MX2013003715A (es) 2013-09-26
JP2013538863A (ja) 2013-10-17
WO2012045569A9 (en) 2016-01-07
JP6000259B2 (ja) 2016-09-28
HUE033204T2 (en) 2017-11-28
EP2624859B1 (en) 2017-03-01
RU2013120033A (ru) 2014-11-20
US20130280236A1 (en) 2013-10-24
EP2624859A1 (en) 2013-08-14
SG188639A1 (en) 2013-05-31
KR20130136988A (ko) 2013-12-13
CA2812888A1 (en) 2012-04-12
MX343784B (es) 2016-11-23
RU2606155C2 (ru) 2017-01-10
PL2624859T3 (pl) 2017-09-29
BR112013008034A2 (pt) 2016-06-14

Similar Documents

Publication Publication Date Title
ERIKSEN et al. Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy
ES2788075T3 (es) Uso terapéutico sinérgico de concentrados de complejo de protrombina con concentrados de FVIII
ES2625153T3 (es) Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución
ES2983341T3 (es) Dispositivo extracorpóreo y matriz para la eliminación de proteínas fibrinolíticas de fluidos biológicos, métodos y usos de los mismos
US20100298223A1 (en) Fibrinogen for treatment of bleeding in trauma and platelet disorders
Ponschab et al. Preferential effects of low volume versus high volume replacement with crystalloid fluid in a hemorrhagic shock model in pigs
ES2742898T3 (es) Composiciones de protrombina humana y factor X activado para mejorar la hemostasia en el tratamiento de trastornos hemorrágicos
Friedman et al. Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients
Gangji et al. Bleeding in patients with renal insufficiency: a practical guide to clinical management
Sharma et al. Tranexamic acid leads to paradoxical coagulation changes during cardiac surgery: a pilot rotational thromboelastometry study
ES2579753T3 (es) Uso del Factor VIIA para tratamiento de complicaciones tardías de traumatismo
ES2913934T3 (es) Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias
Magdesian Acute blood loss
KR20120022717A (ko) 피브리노겐의 신규 용도
HK1188391B (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
HK1188391A (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
Fayed et al. Acute normovolaemic haemodilution in cirrhotic patients undergoing major liver resection: Role of ROTEM
Chiba Serum transfusion as a hemostatic procedure
Groessle et al. Perioperative management of a patient with Bernard-Soulier-Syndrome undergoing major abdominal surgery: 6AP1-8
Kim et al. The effect of hydroxyethyl starch (670/0.75) on hemostasis during acute normovolemic hemodilution: 6AP1-6
Parameswaran et al. The use of recombinant factor VIIa in gastrointestinal bleeding
US20170020995A1 (en) Serine Protease Primary Hemostatic Agent
山田祐輔 et al. Changes in coagulation factor XIII activity during resuscitation for hemorrhagic shock